The use of engineered T cell receptor-like antibody P1C1TM specific for a wild-type p53125-134 peptide in complex with HLA-A24 Class I MHC allele induces selective cytotoxicity and growth inhibition of mutant p53-expressing cells, including those of breast cancer cells, by distinguishing them based on their antigen expression levels 171. Here, TP53 is linked to breast cancer.